European CHMP recommends baloxavir marboxil (Xofluza) for treatment and post-exposure prophylaxis of uncomplicated influenza.

Baloxavir marboxil is an oral antiviral which prevents influenza virus replication by inhibiting cap-dependent endonuclease. It reduces the duration of flu-related symptoms in healthy individuals and individuals at high risk of flu-related complications.

Source:

European Medicines Agency